Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases, Metformin, Dapagliflozin, Hypoglycemic Agents, Pharmacologic Actions, Physiological Effects of Drugs
Eligibility Criteria
Inclusion Criteria:
- Treatment naive males and females, >= 18 years old and
<= 77 years old, with type 2 diabetes mellitus
- Subjects must have central laboratory pre-randomization hemoglobin A1C >= 7.5 and <= 12.0%
- C-peptide >= 1.0 ng/mL (0.34 nmol/L)
- Body Mass Index <= 45 kg/m2
- Must be able to perform self monitoring of blood glucose
Exclusion Criteria:
- aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3X*upper limit of normal (ULN)
- Serum Total bilirubin >2 mg/dL (34.2 µmol/L)
- Creatinine kinase >3*ULN
- Serum creatinine >= 1.50 mg/dL (133 µmol/L) for male subjects, >= 1.40 mg/dL (124 µmol/L) for female subjects
- Calcium value outside of the central laboratory normal reference range
- Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
- Urine albumin:creatinine ratio (UACR) >1800 mg/g (203.4 mg/mmol Cr)
- Severe uncontrolled hypertension defined as systolic blood pressure (SBP) >=180 mmHg and/or diastolic blood pressure (DBP) >=110 mmHg
- Hemoglobin >=11.0 g/dL (110 g/L) for men; hemoglobin >=10.0 g/dL (100 g/L) for women
- Positive for hepatitis B surface antigen
- Positive for anti-hepatitis C virus antibody
- History of diabetes insipidus
- History of diabetic ketoacidosis or hyperosmolar nonketotic coma
- Symptoms of poorly controlled diabetes that would preclude participation in this trial
Sites / Locations
- International Institute Of Clinical Research
- Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc
- Clinical Research Advantage, Inc.
- John Muir Physician Network Clinical Research Center
- Encompass Clinical Research-North Coast
- Southland Clinical Research Center, Inc.
- Valley Research
- Del Rosario Medical Clinic, Inc.
- Irvine Center For Clinical Research, Inc.
- Pacific Sleep Medicine Services (Avastra Clinical Trials)
- Orange County Research Center
- Lynn Institute Of The Rockies
- Radiant Research, Inc.
- Clinical Therapeutics Corporation
- Nextphase Clinical Trials, Inc.
- Baptist Diabetes Associates
- Metabolic Research Institute, Inc.
- Lake Hartwell Family Medicine
- Middle Georgia Drug Study Center, Llc
- Northwest Clinical Trials
- Provident Clinical Research
- Cedar Crosse Research Center
- Deerbrook Medical Associates
- Physicians Research Group
- Borgess Research Institute
- Olive Branch Family Medical Center
- Clinilabs, Inc.
- Metrolina Medical Research
- Pharmquest
- Crescent Medical Research
- Community Health Care, Inc.
- Holzer Clinic, Inc
- Wells Institute For Health Awareness
- Newark Physician Associates
- Daniel G. Williams, Md
- Physician Research, Inc.
- Gilbert Medical Research, Llc
- Tulsa Clinical Research, Llc
- Integris Family Care Yukon
- Williamette Valley Clinical Studies
- Dingmans Medical
- Integrated Medical Group Pc/Fleetwood Clinical Research
- Wellmon Family Practice
- Safe Harbor Clinical Research
- Southeastern Research Associates, Inc.
- Holston Medical Group
- Parkway Medical Group
- Holston Medical Group
- Southwind Medical Specialists
- Dallas Diabetes & Endocrine Center
- Endocrine Associates
- Village Family Practice
- Juno Research, Llc.
- Non-Invasive Cardiovascular, Pa
- Excel Clinical Research
- Texas Center For Drug Development
- Midland Clinical Research Center
- Hill Country Medical Associates
- Covenant Clinical Research, Pa
- S.A.M. Clinical Research Center
- Avastra Clinical Trials
- Seven Corners Medical Center
- Tidewater Integrated Medical Research
- Northwest Clinical Research Center
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
- Local Institution
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Dapagliflozin + Metformin XR
Dapagliflozin + Placebo
Metformin XR + Placebo
Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks
Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks. Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.
Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks